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Objective. To investigate the effect of Embelin, an inhibitor of X-Linked Inhibitor of Apoptosis Protein (XIAP), on inflammation
and bone erosion in a collagen antibody induced arthritis (CAIA) in mice. Methods. Four groups of mice (𝑛 = 6 per group)
were allocated: CAIA untreated mice, CAIA treated with Prednisolone (10mg/kg/day), CAIA treated with low dose Embelin
(30mg/kg/day), and CAIA treated with high dose Embelin (50mg/kg/day). Joint inflammation was evaluated using clinical paw
score and histological assessments. Bone erosion was assessed usingmicro-CT, tartrate resistant acid phosphatase (TRAP) staining,
and serum carboxy-terminal collagen crosslinks (CTX-1) ELISA. Immunohistochemistry was used to detect XIAP protein. TUNEL
was performed to identify apoptotic cells. Results. Low dose, but not high dose Embelin, suppressed inflammation as reflected by
lower paw scores (𝑃 < 0.05) and lower histological scores for inflammation. Low dose Embelin reduced serum CTX-1 (𝑃 < 0.05)
and demonstrated lower histological score and TRAP counting, and slightly higher bone volume as compared to CAIA untreated
mice. XIAP expression was not reduced but TUNEL positive cells were more abundant in Embelin treated CAIAmice. Conclusion.
Low dose Embelin suppressed inflammation and serum CTX-1 in CAIA mice, indicating a potential use for Embelin to treat
pathological bone loss.
1. Introduction
Rheumatoid arthritis (RA) involves changes in the synovial
membrane, including thickening of the synovial lining, per-
sistent infiltration of inflammatory cells, angiogenesis, and
production of inflammatory cytokines leading to subsequent
cartilage and bone degradation. The joint erosion in RA
is associated with increased numbers of bone resorbing
osteoclasts [1]. The proliferation of synovial cells and the
persistence of inflammatory cells in the RA synovium are
associatedwith amarked reduction in apoptosis [2]. Inducing
apoptosis by targeting the upstream pathway with anti-death
receptor 5 (DR5) [3] and soluble Fas monoclonal antibody
[4] was beneficial in an adjuvant induced arthritis rat model
and in a severe combined immunodeficient-HuRAg mouse
model, respectively.
Apoptosis is activated through the extrinsic and/or intrin-
sic pathways. Both pathways converge downstream at the
level of executor caspases such as caspases 3, 6, and 7 [5],
which are directly responsible for morphological changes
in apoptotic cells. The inhibitory apoptotic proteins family
(IAPs) regulate both upstream (caspase-9) and downstream
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caspases (3, 6, and 7) [6] via their baculovirus IAP repeat
(BIR) domain. IAP members are also involved in other pro-
cesses such as protein ubiquitination [7], cell cycle regulation
[8, 9], immune function regulation via regulation of cell sur-
vival [10], and activation of immune cells. Cellular inhibitors
of apoptosis 1 and 2 (cIAP1 and cIAP2) regulate cytokine
and chemokine production by macrophages via regulating
nucleotide-binding oligomerization domain 2 (NOD2) [11].
Additionally, XIAP regulates innate immunity to Listeria
infection [12] and is associated with transforming growth
factor beta (TGF𝛽) [13, 14] and interferes with nuclear factor
kappa-light-chain-enhancer of activated B cells (NF𝜅B) and
mitogen-activated protein kinases (MAPK) signalling via its
BIR1 domain [15].
We have previously reported an increased expression of
two IAP family members, XIAP and survivin, in synovial
tissues from patients with RA [16] and subsequently demon-
strated their modulation by disease modifying antirheumatic
drugs (DMARDs) [17], indicating that inhibiting XIAP
and/or survivin may be a strategy to treat RA. Support-
ing this, studies have demonstrated an association between
serum survivin and joint erosion [18, 19] and the use of
serum survivin levels as an indicator of patient response to
infliximab treatment [20]. Suppression of inflammation in
an antigen induced arthritis mouse by a Smac mimetic A-
4.10099.1 (ABT), an IAP antagonist, supports IAP suppres-
sion as a promising target to treat RA [21].
Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) is
a bioactive compound derived from a natural plant, Embelia
ribes. Its pharmacological actions include antibiotic, anti-
tumour, analgesic, and anti-inflammatory effects [22, 23].
Embelin has been used in acute and chronic models of
skin inflammation in mice [24]. It is a cell permeable,
nonpeptide small molecule inhibitor of XIAP that can be
administered orally; hence it has potential to be an oral
therapy for RA [25–27]. Importantly, Embelin can suppress
receptor activator of nuclear factor kappa-B ligand (RANKL)
induced osteoclastogenesis in vitro in RAW 264.7 cells and
in myeloma and breast cancer cells [28]; however no studies
have assessed the effect of Embelin on bone erosion in vivo.
This study investigated the effect of Embelin on inflam-
mation and bone loss in a mouse model of inflammatory
arthritis, the collagen antibody induced arthritis (CAIA).
2. Methods
2.1. CAIA Mice and Treatment Protocol. Experiments were
performed in accordance with the Australian Code of Prac-
tice for the care and use of animals for scientific pur-
poses (National Health and Medical Research Council) and
approved by the University of Adelaide and Institute of
medical Sciences Ethics Committees (ethics numbers M-
2009-167 and IMVS 75/09, resp.). Induction of arthritis was
performed as previously published [29]. Four groups of mice
(𝑛 = 6 per group) consisted of the following: group 1: CAIA
without treatment, group 2: CAIA treated with Prednisolone
(10mg/kg/day) [30], group 3: CAIA treated with low dose
Embelin (30mg/kg/day), and group 4: CAIA treated with
high dose Embelin (50mg/kg/day). The number of mice
used in each group was kept to a minimum of 6 as the
range 6–8 has been suggested for other RA animal models
[31]. At day 0, all mice were injected with a 150 𝜇L (1.5mg
total) cocktail of collagen type 2 antibodies (Chondrex kit,
Redwood, WA, USA) via the tail vein. On day 3, mice
were injected intraperitoneally (i.p.) with 20 𝜇L (10 𝜇g) of
lipopolysaccharides (LPS). Embelin in PBS/10% EtOH was
administered daily via oral gavage for 7 days (day 4 to day 10).
The selected doses administered were in the range reported
to give a similar reduction in serum sTNF-𝛼 to that seen
with 30mg/kg Prednisolone in acute and chronic models
of skin inflammation in mice [24]. CAIA mice with no
treatment were given the vehicle (PBS/10% EtOH) only. Mice
were humanely killed on day 10 and paws were fixed in 10%
normal buffer formalin overnight and then were washed with
PBS and scanned with microcomputed tomography (micro-
CT) before being decalcified and processed for histological
evaluation. Serum was collected via cardiac puncture and
analysed for CTX-1 using an enzyme-linked immunosorbent
assay (CTX-1 ELISA, Ratlaps).
2.2. Micro-CT Scans and Image Analysis. To measure bone
erosion, micro-CT scans of the paws were performed
(SkyScan 1076, Kontich, Belgium) ex vivo. The scanning
parameters used were as follows: tube voltage 74 kV, tube cur-
rent 136 𝜇A, isotropic pixel size 17.4 𝜇m, 1.0mm aluminium
filter, and one frame averaging [29].
Cross-sectional images of the front right paws were
reconstructed (NRecon, SkyScan) and aligned using the long
axis of the paw as reference (Dataviewer, SkyScan). The
right radiocarpal joint was chosen for quantitation of the
bone volume (BV) [29]. The volume of interest included
40 cross-sections (=0.7mm) below the epiphyseal growth
plate (EGP) to 100 cross-sections (1.7mm) above the EGP
(CTAn V.1.12.04, SkyScan). Grey level images were binarized
into bone and nonbone using a uniform threshold (CTAn,
SkyScan) [29, 32]. BV (measured in mm3) was calculated as
the volume occupied by the voxels segmented as bone (CTAn,
SkyScan) [29, 32].
2.3. Clinical Paw Scoring. Paw scoring was performed daily
from day 0 to day 10, by two observers given to each group
using a system previously described [33]. In addition, each
group was presented randomly for scoring. For each paw a
score of 1 was given for each single digit involved; a range
of 0–5 was given for swelling of carpal/tarsal and 0–5 for the
wrist/ankle [33]. Therefore, the maximal score for each paw
could be 15 and the maximal score for each mouse could be
60. Other parameters measured included body weight and
daily clinical observations of general health.
2.4. Histological Evaluation
2.4.1. Inflammation Score, Cartilage and Bone Degradation
Score, and Pannus Score. A score for cellular infiltration
(inflammation score), cartilage and bone degradation, and
pannus formation was assigned to the hematoxylin-eosin
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(HE) stained paw specimens according to publishedmethods
[29]. Inflammation within the radiocarpal/metatarsal joints
was scored as 0 to 3: score 0 ≤ 5% inflammatory cells, score
1 = 6–20%, score 2 = 21–50%, and score 3 = more than 50%
inflammatory cells. Cartilage/bone degradation was scored:
0 = normal bone integrity, 1 = mild cartilage destruction,
2 = evidence of both cartilage and bone destruction, 3 =
severe cartilage and bone destruction. Pannus formation was
scored as 0 = no pannus formation and 1 = pannus formed.
Histological scoring was performed by two independent
observers that were blinded as to the group allocation.
2.4.2. TRAP Staining. TRAP staining was performed based
on a previously published method [34–36]. TRAP positive
cells with 3 or more nuclei within the metatarsal and
metacarpal joints of the paws were counted using a light
microscopewith 100xmagnification (NIKOND1 digital cam-
era attached to NIKON FXA research microscope, Japan).
2.4.3. XIAP Immunohistochemistry. XIAP expression was
detected in paw tissues from all mice using the Vectastain
Elite ABC Kit Universal (PK-6200, Vector Labs, Burlingame,
CA), according to published methods [37]. The primary
antibody was rabbit polyclonal anti-mouse XIAP (Abcam,
Ab21278, Sapphire Bioscience Pty. Ltd., NSW, Australia)
at 2𝜇g/mL. Negative controls included omission of pri-
mary antibodies or isotype control (rabbit universal iso-
type IgG, DakoCytomation, Glostrup, Denmark). Sections
were stained with 3-amino-9-ethylcarbazole (AEC) dye (Cat.
K3469; DakoCytomation, Glostrup, Denmark) and counter-
stained with hematoxylin and lithium carbonate. Semiquan-
titative analysis of XIAP immunostaining was performed
according to previously published method [38].
2.4.4. Terminal Deoxynucleotidyl Transferase dUTP Nick End
Labelling (TUNEL). TUNEL was performed on paw tissues
for apoptosis assessment using an in situ cell death detection
kitAP (RocheDiagnosticAustralia Pty. Ltd.,NSW,Australia),
as previously published [16]. Tissue was incubated with label
solution only for a negative control or with DNA-ase for a
positive control for the presence of fragmented DNA. Colour
was developed using fast red (Vector Labs, CA, USA) and
counterstained with hematoxylin and lithium carbonate.
2.4.5. Serum CTX-1 ELISA. Serum CTX-1 was measured
in duplicate for each sample or standard using Ratlaps
CTX-1 ELISA according to the manufacturer instructions
(Immunodiagnostic Systems, Nordic) [39]. The optical den-
sity wasmeasured at 450 nmusing a Power-Wave ELISA plate
reader and software KC4 (Biotek Instruments,Winooski, VT,
USA). SerumCTX-1 concentrationwas interpolated from the
standard curve generated.
2.4.6. Statistical Analysis. Differences in mean values of each
parameter between groups were analysed using the Kruskal-
Wallis statistical test and differences between two groupswere
analysed using Mann-Whitney U test. Correlation between
two parameters was analysed using Kendall’s tau b-test. All
statistical analysis was performed using SPSS version 20
(Chicago, IL,USA).A𝑃 value of less than 0.05was considered
statistically significant.
3. Results
3.1. CAIAMice Treated with Low Dose Embelin Demonstrated
Lower Paw ScoresThanUntreated CAIAMice. The front paws
in the CAIAmice exhibited inflammation as assessed by clin-
ical paw score (Figure 1(a)). Prednisolone treated CAIAmice
(a positive treatment control) consistently demonstrated
lower mean paw scores compared to CAIA untreated mice
throughout the experiment (𝑃 < 0.05). CAIA mice treated
with a low dose of Embelin also demonstrated markedly
lower paw scores throughout the experiment (Figure 1(b))
with statistically significant differences observed on day 6
(𝑃 < 0.05). Although the mice treated with high dose
Embelin demonstrated lower mean paw scores, these were
not significant statistically when compared to the CAIA
untreated group.
Themice bodyweights did not differ between groups over
the course of the experiment (data not shown).
3.2. CAIAMice Treated with LowDose Embelin Demonstrated
Lower Scores for Inflammation, Cartilage and Bone Degrada-
tion, and Pannus Formation. Histological evaluation of all
four paws of all mice showed that CAIA mice treated with
low dose Embelin had lower scores for cellular infiltration
(𝑃 = 0.05), cartilage and bone degradation (𝑃 = 0.071), and
pannus formation (𝑃 = 0.167) compared to CAIA untreated
mice. Representative HE stained images of the front right
paw from each group are shown (Figure 2(a)). All histological
scores were significantly lower in Prednisolone treated CAIA
mice compared to untreated CAIA mice (Figure 3).
3.3. CAIAMice Treated with Low Dose Embelin Demonstrated
Lower but Not Significantly Different Number of TRAPPositive
Osteoclasts. TRAP staining was performed on sections from
all four paws of each mouse to identify the number of
preosteoclast/osteoclast cells. Representative images of TRAP
staining of the front right paw from each group are presented
in Figure 2(b). Multiple TRAP positive cells were observed
within the joint and pannus region of CAIA mice (mean ±
standard error of themean, 57.27± 17.52) and thiswas reduced
with Prednisolone treatment (20.43 ± 7.31) and to a lesser
degree in CAIA treatedwith low dose Embelin (45.33± 15.13).
Interestingly, CAIA mice treated with high dose Embelin
demonstrated similar number of TRAPpositive cells to CAIA
untreated mice (57.09 ± 21.00) (Figures 2(b) and 3).
3.4. There Was No Difference in XIAP Protein Expression
between CAIA Mice Treated with Low or High Dose Embelin
andCAIAUntreatedMice. Semiquantitative analysis of XIAP
immunostaining revealed that mouse paws from all groups
expressed XIAP proteins within cells in pannus, periosteal
tissue, articular cartilage, and bone marrow (Figure 4(a)).
There was no statistical significant difference in the XIAP
expression within the joint space between the groups. Mean
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Figure 1: (a) Representative clinical features of mouse paws in CAIA untreated mice, Prednisolone treated CAIA mice, CAIA mice treated
with low dose Embelin, and CAIA mice treated with high dose Embelin. (b) Mean clinical paw scores of each study group throughout the
experiment. Error bars represent standard error of the mean (SEM).
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Figure 2: (a) Representative hematoxylin-eosin staining within the radiocarpal joint from each mouse group. (b) Representative TRAP
staining (red) in the radiocarpal joint from each mouse group. Hematoxylin counterstaining.
(±SEM) score for XIAP was 0.59 ± 0.3 for CAIA untreated
mice, 0.85 ± 0.05 for CAIA treated with Prednisolone, 0.62 ±
0.29 for CAIA treated with low dose Embelin, and 0.81 ± 0.39
for CAIA treated with high dose Embelin.
3.5. CAIA Mice Treated with Low and High Dose Embelin
Demonstrated IncreasedNumbers of Apoptotic Cells Compared
with CAIAUntreatedMice. To investigate if Embelin induced
apoptosis in CAIA mice, evidence of fragmented DNA was
assessed using TUNEL. Fewer TUNEL positive cells were
observed within the pannus of the CAIA mice, compared to
prednisolone treated CAIAmice and both low and high dose
Embelin treated CAIA mice (Figure 4(b)).
3.6. Higher but Not Significant Bone Volume (BV) Was
Observed in CAIA Mice Treated with Low and High Dose
Embelin Compared to CAIA Untreated Mice. Three-dimen-
sional reconstruction of front right paws by micro-CT
demonstrated severe osteolysis within their radiocarpal and
PIP (proximal interphalangeal) joints of the untreated CAIA
mice in marked contrast to Prednisolone treated CAIA mice
(Figure 5(a)). There was a significantly higher mean BV







































Figure 3: Histological and TRAP scores (obtained using scores as
described in Section 2) on paw tissues at day 10. Bars representmean
± SEM. ∗𝑃 < 0.05.
within the radiocarpal region in the Prednisolone treated
CAIA mice, compared to CAIA untreated mice (1.73 ± 0.02
versus 1.43 ± 0.06, 𝑃 = 0.011) (Figures 5(b) and 5(c)).
Although the mean BV was higher in both low and high
dose Embelin treated groups (1.47 ± 0.05 and 1.57 ± 0.06,
resp.) compared to the CAIA untreated group, there was no
statistically significant difference (Figure 5(c)).
3.7. CAIAMice Treated with Low Dose Embelin Demonstrated
Significantly Lower Serum CTX-1 Levels Than the Untreated
CAIA Mice. Serum CTX-1 was measured as a marker of
systemic bone resorption in all groups. Levels were signifi-
cantly lower in the Prednisolone treated CAIA group (25.28
± 3.35 ng/mL) as compared to CAIA untreated mice (33.27 ±
0.85,𝑃 = 0.017).There was significantly lower levels of serum
CTX-1 (25.12 ± 1.91) in mice treated with low dose Embelin
compared to CAIA untreated mice (𝑃 = 0.016). Although
CTX-1 levels were lower in the high dose Embelin treated
group, they were not statistically significant (Figure 5(d)).
3.8. CorrelationAnalysis of Parameters. Correlations between
clinical and histological scores were made using data from
four paws of each of the mice. Only data from the front right
paw was correlated with the micro-CT data. Overall, there
was a strong and significant correlation between the clinical
paw score and each of the histological scores (Figure 6).There
was also a significant strong inverse correlation (𝜏 = −0.525,
𝑃 = 0.004) between BV as assessed by micro-CT and the
cartilage and bone scores assessed histologically. The inverse
correlation betweenBVassessed bymicro-CT and the clinical
paw score was also strong (𝜏 = −0.531) and statistically
significant (𝑃 = 0.004).
4. Discussion
This study demonstrates low dose Embelin suppressed joint
inflammation and bone erosion in a CAIA model in mice.
The findings support a previous study in a model of antigen
induced arthritis mice by Mayer et al. [21] where inhibition
of IAP using a Smac mimetic suppressed disease activity.
In the study by Mayer et al. an antigen induced arthritis
was used to assess the initial immune response, whereas the
current results demonstrate effects of an XIAP inhibitor on
the effector phase of disease. In the antigen induced arthritis
model, disease induction involves stimulation of antibody
production by the host, via administration of antigen (bovine
serum albumin), while in CAIA model this initiation stage
is bypassed by the administration of antibodies to collagen
antibody type 2. While the IAP inhibitor A-4.10099.1 (ABT)
was given intravenously in the Mayer study [21], the XIAP
inhibitor (Embelin) used in our study was given via oral
gavage, suggesting a potential oral treatment for RA patients.
It is important to note that the IAP inhibitor A-4.10099.1
(ABT) was given prior to the disease onset (prophylactic
scheme) while in our study the Embelin was assessed for
its therapeutic effects with treatment commencing following
disease induction.
Mayer et al. [21] elucidated the molecular mechanism
involved in suppression of inflammation using a Smac
mimetic, IAP antagonist A-4.10099.1 (ABT) with a particular
focus on endothelial signaling. However, the study did not
report microscopic features of mouse joint damage or assess
bone erosion. In the current study, we demonstrate that
the XIAP inhibitor, Embelin, used in low dose, suppressed
inflammation clinically and microscopically in CAIA mice
and we provided evidence of suppression of bone erosion
using histological assessment, TRAP counting, micro-CT,
and serum CTX-1 assay.
The mechanism by which Embelin suppresses inflam-
mation has been investigated in various in vivo models of
inflammation. In an LPS induced mouse model of skin
inflammation, Embelin was reported to reduce cutaneous
TNF-𝛼 expression [24]. In acetic acid induced colitis Embelin
reduced the activity of colonic myeloperoxidase (MPO),
lipid peroxides, and serum lactate dehydrogenase as well
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Figure 4: (a) XIAP protein expression (red) in the radiocarpal joint in CAIA mice, in Prednisolone treated mice, in CAIA mice treated with
low dose Embelin, and in CAIAmice treatedwith high dose Embelin. (b) Representative TUNEL staining (indicated in red) in the radiocarpal













































































































Figure 5: (a) Three-dimensional reconstruction of front right paw in each study group. Arrows point out bone area with erosion. (b) Three-
dimensional reconstruction of the radiocarpal region from eachmouse group chosen for quantitation of bone volume. (c)Mean bone volume
(BV, expressed inmm3) analysed bymicro-CT in each group. (d)Mean serumCTX-1 level in eachmouse group. Error bars represent standard
error of the mean (SEM).
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Figure 6: Bivariate correlations between clinical score, bone volume or serum CTX-1 (𝑦-axis), and histological scores (inflammation score
or cellular infiltration score, cartilage and bone degradation score, and pannus score).
as significantly increasing the reduced glutathione [40]. In
dextran sodium sulphate (DSS) induced colitis in mice,
Embelin reduced the mRNA expression of TNF-𝛼, IL-1, IL-
6, and colonic MPO [41].
The Mayer et al. study suggested that apoptosis was not
the mechanism of action of the IAP antagonist A-4.10099.1
(ABT) in abrogating inflammation in antigen induced arthri-
tis mice. They reported that A-4.10099.1 (ABT) regulated
the inflammatory processes by attenuation of leucocyte-
endothelial cell interaction and decreased TNF-𝛼 induced
activation of TGF𝛽 activated kinase-1, p38, and cJun N
terminal kinase. Smac mimetics can target at least three
members of IAPs (cIAP1, cIAP2, and XIAP) and therefore
are a broader IAP inhibitor than Embelin. cIAPs have been
reported to interfere with the type 2 TNF receptor signaling
[6] in addition to directly binding to cleaved caspases 3, 7, and
9 [42].
We demonstrated positive TUNEL staining in the resid-
ual inflammatory cells in mice treated with Embelin suggest-
ing that Embelin induced apoptosis in these cells. However,
nonresponder mice in the Embelin treated groups demon-
strated a very low positivity of TUNEL staining within the
pannus suggesting some resistance of inflammatory cells
to Embelin induced apoptosis. This correlates with our
immunohistochemical evaluation of XIAP protein expres-
sion. We observed Embelin reduced XIAP expression within
the pannus of responder mice in the group treated with low
dose Embelin (𝑛 = 4), while in the nonresponder mice (𝑛 =
2) there were very low XIAP levels, low TUNEL staining, and
persistence of pannus despite receiving Embelin treatment
(data not shown). This suggests that Embelin may only be
beneficial if the pannus has high levels of XIAP expression.
An in vitro study using leukemia cells observed that Embelin
reduced XIAP protein expression as detected by western
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blot [43]. However, a study on glioma cells demonstrated no
suppression of XIAP protein despite induction of apoptosis,
suggesting suppression of other antiapoptoticmolecules such
as Bcl2 and Bcl-XL in these cells [44].
The mechanism of action of Embelin in suppressing
bone resorption has only been investigated in vitro. In this
study Embelin suppressed RANKL induced activation of
osteoclasts via inhibiting NF𝜅B, inhibition of I𝜅B𝛼 phos-
phorylation, and I𝜅B𝛼 degradation in RAW 267.4 cells [28].
Consistent with this, our study is the first to show Embelin
suppression of bone erosion in an in vivomodel.
Dose-dependent effects of Embelin (10, 30, and 50mg/kg)
have been reported previously in DSS induced colitis in
mice [41]; however, in our study the lower dose was more
effective than the higher dose. This is also in agreement with
a previous study that reported the ED50 of Embelin in LPS
induced mouse model of skin inflammation to be 9.8mg/kg
[24]. A similar trend to what we observed with Embelin was
seen in a study which investigated the effect of methotrexate
in CIA mice [45]. They observed that methotrexate given
at 2.5mg/kg was the most effective dose as compared to
0.1 and 5mg/kg. The highest dose (5mg/kg) in that study
resulted in a higher clinical score, similar towhatwe observed
with a higher dose of Embelin, which indicates that an
optimal dose to reduce the inflammation in arthritis model
is not necessarily the highest dose. It is possible that higher
dose Embelin failed to suppress inflammation in this model
because it has reached a threshold where upregulation of
cIAPs occurred as a compensatory mechanism for higher
level of XIAP suppression [46]. cIAPs upregulation sub-
sequently can form a complex with TRADD resulting in
activation of downstream inflammatory signalling pathways
which may maintain inflammation. Further studies to eluci-
date the involvement of other IAPmembers in compensatory
inhibition of IAP members in this setting are warranted.
In this study, both front paws of each mouse had higher
paw scores with most of the mice having highest paw score
in the front right paws and hind paws were rarely involved.
Based on this observation, micro-CT evaluation was per-
formed on the front right paws. The reduced involvement of
hind paws in our CAIA model could possibly be due to the
administration of a lower dose of both the cocktail antibody
to collagen type 2 and LPS compared to other studies [47].
However, the use of a lower concentration of antibody and
LPS resulted in less harmful effects to thesemice and possibly
is more relevant to the clinical situation in human RA where
involvement of all joints is rarely seen.
Ourmicro-CT analysis showed thatmice treatedwith low
dose Embelin exhibited less bone erosion compared to CAIA
untreated mice, although the difference was not statistically
significant, possibly because a small number (only front
right paws from each mouse) was analysed. The evidence
of reduced bone damage was supported by the significant
decrease in serum CTX-1 level. Nonetheless, BV assessed by
micro-CTdemonstrated significant positive correlationswith
both clinical and histological scores and at the same time
demonstrated significant negative correlations with serum
CTX-1. Overall, this supports the evidence of increased bone
damage in untreated CAIA mice compared to CAIA mice
treated with Prednisolone and low dose Embelin. Moreover,
this confirms micro-CT as an objective quantitative method
for assessing bone erosion in a rodent model of arthritis
[48, 49].
A recent study involving 108 RA patients receiving low
dose Prednisolone and 117 healthy controls has reported that
serum CTX-1 (a marker for bone resorption) measured at
0, 3, and 12 months following treatment was significantly
lower in the Prednisolone treated group [50]. The current
study indicated differences in CTX-1 levels between being
untreated and Prednisolone or low dose Embelin treatment,
suggesting that serum CTX-1 is sensitive for measurement of
bone damage.
Our study supports the induction of apoptosis using low
dose Embelin to reduce inflammation and bone erosion in a
murine model of inflammatory arthritis. Given the multiple
roles of XIAP, further studies on Embelin’s mechanism of
action to interfere with various signalling pathways in this
model are needed.The present study investigated the effect of
Embelin in an inflammatory arthritis model that mimics the
effector phase of RA; thus studies using Embelin in animal
models mimicking the initial stage of RA, such as collagen
induced arthritis (CIA) or antigen induced arthritis, will
provide further information on the effect of Embelin in the
initiation phase of the disease.
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